Clinical trials
Amyloidosis clinical trials
Below are recruiting amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 155 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07232459Recruiting
PET imaging for amyloidosis in the heart
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
Hefei, AnhuiAges 18 years+ - NCT07238426Enrolling by invitation
Heart screening for older adults in Ordu, Turkey
This study is a screening program in Ordu, Turkey, to find older adults (65+) who might have a heart condition called cardiac amyloidosis. It uses medical records and heart ultrasounds to check people who already have certain heart problems.
Ordu, OrduAges 65 years+ - NCT07103863Enrolling by invitation
Imaging test for predicting AL cardiac amyloidosis outcomes
This study uses two types of imaging (PET/CT and MRI) to see if they can better predict outcomes for people with AL cardiac amyloidosis. The goal is to improve how doctors understand and manage the disease.
Beijing, Beijing MunicipalityAges Any age - NCT04667494RecruitingPhase 4
Ultrasound treatment for heart amyloidosis
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
Boston, MassachusettsAges 18–90 - NCT06569147RecruitingPhase 1/Phase 2
Elranatamab for AL amyloidosis that has returned or not responded
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
New Haven, ConnecticutAges 18 years+ - NCT07771621Enrolling by invitationPhase 1
PET scan for detecting heart amyloidosis
This study tests a new PET imaging agent that may help doctors see amyloid buildup in the heart more clearly. It may help people with heart amyloidosis or those suspected of having it.
St Louis, MissouriAges 18 years+ - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
La Jolla, CaliforniaAges 18–85 - NCT07223203RecruitingPhase 3
Study of nucresiran for hereditary nerve condition (hATTR-PN)
This trial tests a new medicine called nucresiran for people with a rare genetic nerve condition (hATTR-PN). The goal is to see if it can slow down or improve nerve damage.
Aurora, ColoradoAges 18–85 - NCT06355934Recruiting
Observational study of ATTR amyloidosis treatment patterns
This study looks at the health records of people with ATTR amyloidosis to understand how the disease is treated and what happens over time. It helps doctors learn more about this condition so they can improve care.
Eden Prairie, MinnesotaAges Any age - NCT07752732Recruiting
Heart scans for amyloidosis in people with severe aortic valve stenosis
This study looks at how often cardiac amyloidosis occurs in people with severe aortic valve stenosis. It uses different heart scans to find out more. If you have both conditions, this research may help doctors understand your situation better.
TübingenAges 18 years+ - NCT06907186Recruiting
Psychological support program for amyloidosis patients and families
This study tests a structured psychological support program for people with hereditary transthyretin amyloidosis (ATTRv) with heart involvement, their caregivers, and those who carry the gene but have no symptoms yet. The goal is to see if the program is practical and well-accepted.
PaviaAges 18 years+ - NCT06420167RecruitingPhase 2
Dapagliflozin for kidney AL amyloidosis
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
Detroit, MichiganAges 18 years+ - NCT02952144Recruiting
Study of Lixelle for amyloid disease in dialysis
This study looks at whether Lixelle helps treat dialysis-related amyloidosis in people who receive hemodialysis three times a week. It may help reduce symptoms caused by amyloid deposits that can build up in tissues over time.
New York, New YorkAges Any age - NCT06082050RecruitingEarly Phase 1
YOLT-201 for transthyretin heart disease
This trial tests a new intravenous medicine called YOLT-201 for people with a heart condition caused by buildup of a protein called transthyretin (ATTR-CM). The goal is to see if it can slow or improve the disease.
Hangzhou, ZhejiangAges 18–80 - NCT06354322Recruiting
Genetic study for unclassified autoinflammatory disease or AA amyloidosis
This study looks for genetic causes of hard-to-diagnose autoinflammatory diseases or a related condition called AA amyloidosis. It aims to find answers for people whose condition does not fit any known type, by studying their genes and medical history.
ParisAges 3–80 - NCT06291805Recruiting
Understanding wtATTR-CM heart disease (TRACE 1)
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
Aarhus, Arrhus NAges 18 years+ - NCT06978660Recruiting
AI-powered ECG test for early cardiac amyloidosis
This trial tests if an AI can spot early signs of cardiac amyloidosis from a standard 10-second ECG. If successful, it could lead to faster diagnosis and treatment.
Evanston, IllinoisAges 18 years+ - NCT07151690RecruitingPhase 2
BCMA/CD3 bispecific antibody for newly diagnosed AL amyloidosis
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
TianjinAges 18 years+ - NCT07039578RecruitingPhase 2
Study of CM336 for light-chain amyloidosis
This trial tests a new injection called CM336 for people with light-chain amyloidosis that has come back or not responded to other treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07124377Recruiting
Study of hereditary ATTR amyloidosis symptoms
This study looks at how a specific genetic change (Val50Met) affects people with hereditary ATTR amyloidosis. It may help doctors better understand the condition and its symptoms.
Charata, Chaco ProvinceAges 20 years+ - NCT07266116RecruitingPhase 1/Phase 2
TQB2934 injection for light chain amyloidosis
This trial tests a new injectable drug called TQB2934 for people with systemic light chain amyloidosis. It aims to see if the drug is safe and effective for those whose disease has come back or gotten worse after previous treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT07033715Recruiting
Exercise for hereditary ATTR amyloidosis in Portugal
This trial tests whether a structured exercise program can help people with hereditary ATTR amyloidosis (a condition that affects nerves and organs). It is for people in Portugal with early to moderate disease who can safely exercise.
Maia, Porto DistrictAges 18 years+ - NCT06998875RecruitingPhase 4
Study of avastin and tofacitinib for skin amyloidosis
This trial looks at people with primary cutaneous amyloidosis who have been treated with Avastin Capsules or Tofacitinib Citrate. It aims to track how well these medications work and if they are safe over time.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06803082Recruiting
How systemic light chain amyloidosis affects the eyes
This study looks at how systemic light chain amyloidosis, a condition where abnormal proteins build up in organs, may affect your eyes. By comparing eye exams of people with and without the disease, researchers hope to learn more about eye-related changes so they can improve care.
Guangzhou, GuangdongAges 18–80
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloidosis?
- Yes. Clin2 currently lists 155 recruiting amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.